{ "company": "Quidel Corporation", "ticker": "QDEL", "period": { "from": "2026-03-12", "to": "2026-04-11", "days": 30 }, "sentiment_breakdown": { "positive": 23, "negative": 10, "neutral": 14 }, "synthesis": { "executive_summary": "Sentiment analysis for Quidel Corporation (QDEL) from 2026-03-12 to 2026-04-11. Analyzed 47 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.", "date": "2026 Apr 2", "source": "pubmed", "score": 0.67 }, { "title": "QuidelOrtho Corp. Hits Day High with Strong 8.33% Intraday Surge", "date": "2026-03-18", "source": "alpha_vantage", "score": 0.511 }, { "title": "QuidelOrtho (QDEL) Welcomes New Chief Legal Officer", "date": "2026-03-25", "source": "alpha_vantage", "score": 0.494 }, { "title": "QuidelOrtho, Lifotronic Technology to Expand Global Immunoassay Portfolio", "date": "2026-04-10", "source": "alpha_vantage", "score": 0.318 }, { "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?", "date": "2026-04-08", "source": "alpha_vantage", "score": 0.296 }, { "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?", "date": "2026-04-07", "source": "alpha_vantage", "score": 0.296 }, { "title": "Vanguard disaggregates holdings; reports 0 shares of QuidelOrtho (QDEL)", "date": "2026-03-28", "source": "alpha_vantage", "score": 0.296 }, { "title": "QuidelOrtho Corporation $QDEL Shares Acquired by Aristotle Capital Boston LLC", "date": "2026-03-15", "source": "alpha_vantage", "score": 0.296 }, { "title": "ArrowMark Colorado Holdings LLC Sells 181,325 Shares of QuidelOrtho Corporation $QDEL", "date": "2026-03-15", "source": "alpha_vantage", "score": 0.296 }, { "title": "QuidelOrtho (NASDAQ:QDEL) Rating Increased to Buy at Wall Street Zen", "date": "2026-04-04", "source": "alpha_vantage", "score": 0.273 } ], "top_negative": [ { "title": "UBS cuts Quidel stock price target on weaker respiratory season", "date": "2026-04-10", "source": "alpha_vantage", "score": -0.625 }, { "title": "QuidelOrtho Corp stock hits new 52-week low amid persistent financial struggles and biotech sector headwinds", "date": "2026-03-21", "source": "alpha_vantage", "score": -0.557 }, { "title": "QuidelOrtho Corp. Hits Day Low of $16.16 Amid Price Pressure", "date": "2026-03-20", "source": "alpha_vantage", "score": -0.511 }, { "title": "EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.473 }, { "title": "QuidelOrtho (QDEL) Is Down 18.0% After Proposed NIH Funding Cuts Raised Diagnostics Demand Questions", "date": "2026-04-09", "source": "alpha_vantage", "score": -0.402 }, { "title": "UBS Maintains QuidelOrtho(QDEL.US) With Hold Rating, Cuts Target Price to $17", "date": "2026-04-10", "source": "alpha_vantage", "score": -0.296 }, { "title": "QuidelOrtho Corp. Stock Plummets to New 52-Week Low of $14.45", "date": "2026-03-30", "source": "alpha_vantage", "score": -0.273 }, { "title": "Precision Trading with Quidelortho Corp Com (QDEL) Risk Zones", "date": "2026-03-27", "source": "alpha_vantage", "score": -0.273 }, { "title": "QuidelOrtho Corp. Stock Plummets to New 52-Week Low at $17.03", "date": "2026-03-19", "source": "alpha_vantage", "score": -0.273 }, { "title": "High-Sensitivity Cardiac Troponin T-gen6 Assay in Suspected Myocardial Infarction: Diagnostic Accuracy, Cutoffs, and Clinical Implications.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.226 } ], "raw_data": { "total_items": 47, "items": [ { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-24", "url": "https://www.sec.gov/Archives/edgar/data/1906324/000119312526120684/0001193125-26-120684-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho, Lifotronic Technology to Expand Global Immunoassay Portfolio", "url": "https://www.mpo-mag.com/breaking-news/quidelortho-lifotronic-technology-to-expand-global-immunoassay-portfolio/", "date": "2026-04-10", "summary": "QuidelOrtho has formed a long-term strategic supply agreement with Lifotronic Technology Co. Ltd. to enhance its global immunoassay portfolio. This collaboration will provide QuidelOrtho access to new high-throughput and low-to-mid volume immunoassay analyzer platforms and more than 25 new assays, expanding its offerings in key international markets outside the United States. The partnership aims to deliver scalable, cost-efficient diagnostic solutions and increase competitiveness in internation", "sentiment_score": 0.401437, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "UBS cuts Quidel stock price target on weaker respiratory season", "url": "https://m.uk.investing.com/news/stock-market-news/ubs-cuts-quidel-stock-price-target-on-weaker-respiratory-season-93CH-4602756?ampMode=1", "date": "2026-04-10", "summary": "UBS has lowered its price target for Quidel Corp. (NASDAQ:QDEL) to $17 from $30, while maintaining a Neutral rating, due to an anticipated weaker respiratory season. The firm revised its estimates ahead of Q1 earnings, noting that much of the negative news regarding China diagnostics is already factored into the stock's recent 53% decline. Investor focus remains on Quidel's non-respiratory business growth, China diagnostics, and free cash flow visibility.", "sentiment_score": -0.311679, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "UBS Adjusts Price Target on QuidelOrtho to $17 From $30, Maintains Neutral Rating", "url": "https://www.marketscreener.com/news/ubs-adjusts-price-target-on-quidelortho-to-17-from-30-maintains-neutral-rating-ce7e50d9d98ef12d", "date": "2026-04-10", "summary": "UBS has significantly lowered its price target for QuidelOrtho (QDEL) to $17 from $30, while continuing to maintain a Neutral rating on the stock. This adjustment comes after QuidelOrtho announced its Q4 2025 earnings, which saw a decline in earnings despite a rise in revenue. The company also provided guidance for its fiscal year 2026.", "sentiment_score": -0.21247, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "UBS Maintains QuidelOrtho(QDEL.US) With Hold Rating, Cuts Target Price to $17", "url": "https://www.moomoo.com/news/post/68158826/ubs-maintains-quidelortho-qdelus-with-hold-rating-cuts-target-price", "date": "2026-04-10", "summary": "UBS has reiterated its Hold rating on QuidelOrtho (QDEL.US) but has lowered its target price for the stock to $17. This adjustment reflects an updated outlook from the firm regarding the company's financial prospects.", "sentiment_score": -0.284666, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (QDEL) Is Down 18.0% After Proposed NIH Funding Cuts Raised Diagnostics Demand Questions", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/quidelortho-qdel-is-down-180-after-proposed-nih-funding-cuts", "date": "2026-04-09", "summary": "QuidelOrtho's stock dropped 18.0% following a proposed US federal budget for 2027 that includes a US$5.00 billion cut to the National Institutes of Health. This news has intensified concerns about future research funding in healthcare, adding uncertainty to the diagnostics market. Despite the stock decline, analysts' price targets remain above the current price, indicating that the fundamental outlook hasn't drastically changed, though market sentiment is highly sensitive to policy shifts regard", "sentiment_score": -0.381872, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-it-time-to-reassess-quidelortho-qdel-after-the-recent-sha", "date": "2026-04-08", "summary": "This article examines QuidelOrtho (QDEL) after a significant share price decline, finding it undervalued according to Discounted Cash Flow (DCF) and Price/Sales (P/S) analyses. The DCF model suggests an intrinsic value of US$80.65 per share, indicating an 80.3% undervaluation compared to its current price of US$15.88. Additionally, its P/S ratio of 0.40x is well below industry averages and its proprietary Fair Ratio, further suggesting undervaluation.", "sentiment_score": 0.256644, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-it-time-to-reassess-quidelortho-qdel-after-the-recent-sha/amp", "date": "2026-04-07", "summary": "QuidelOrtho (QDEL) has experienced significant share price declines over various periods, prompting a reassessment of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is currently 80.3% undervalued, with an intrinsic value of US$80.65 per share against a recent price of US$15.88. Additionally, its Price-to-Sales (P/S) ratio of 0.40x is significantly below the industry average and Simply Wall St's Fair Ratio, also indicating undervaluation.", "sentiment_score": 0.420642, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp (QDEL) Trading Down 5.04% on Apr 6", "url": "https://www.gurufocus.com/news/8776422/quidelortho-corp-qdel-trading-down-504-on-apr-6?mobile=true", "date": "2026-04-06", "summary": "QuidelOrtho Corp (QDEL) shares fell 5.04% on April 6th, reaching an intraday low of $16.20 before closing at $16.38. This places the stock significantly below its 52-week high but above its 52-week low. Wall Street analysts and GuruFocus estimate a substantial upside for QDEL, with average price targets suggesting a \"Hold\" recommendation.", "sentiment_score": -0.229778, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (NASDAQ:QDEL) Rating Increased to Buy at Wall Street Zen", "url": "https://www.marketbeat.com/instant-alerts/quidelortho-nasdaqqdel-rating-increased-to-buy-at-wall-street-zen-2026-04-04/", "date": "2026-04-04", "summary": "Wall Street Zen has upgraded QuidelOrtho (NASDAQ:QDEL) from \"hold\" to \"buy,\" despite a mixed consensus from other analysts, resulting in an average \"Reduce\" rating and a $31.50 price target. The company recently surpassed quarterly earnings and revenue estimates, reporting $0.46 EPS and $723.6M revenue. Additionally, insider buying activity by the CFO and a director suggests confidence, with significant share purchases totaling approximately $568k.", "sentiment_score": 0.108268, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp Stock: Navigating Diagnostics Leadership Amid Sector Evolution and Investor Opportu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/quidelortho-corp-stock-navigating-diagnostics-leadership-amid-sector/69047279", "date": "2026-04-01", "summary": "QuidelOrtho Corp (ISIN: US7476011036) is a significant entity in in vitro diagnostics, specializing in point-of-care testing and immunoassay markets. This analysis from early 2026 delves into its business model, competitive landscape, and strategic watchpoints. The company's dual-track approach featuring rapid diagnostics and lab-based assays, along with its focus on recurring revenue from consumables, positions it for continued growth amidst evolving healthcare demands and increasing decentrali", "sentiment_score": 0.031002, "sentiment_label": "Neutral", "relevance_score": 0.336732, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp. Stock Plummets to New 52-Week Low of $14.45", "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-stock-plummets-to-new-52-week-low-of-1445-3926327", "date": "2026-03-30", "summary": "QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of $14.45, marking a significant 64.06% decline in its 1-year performance. The company has faced negative financial results for 12 consecutive quarters, a high debt-equity ratio of 1.31, and a consistent underperformance compared to the S&P 500. This plummet reflects ongoing difficulties and a challenging year for the company.", "sentiment_score": -0.841625, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "Vanguard disaggregates holdings; reports 0 shares of QuidelOrtho (QDEL)", "url": "https://www.stocktitan.net/sec-filings/QDEL/schedule-13g-a-quidel-ortho-corp-amended-passive-investment-disclosur-44c882a5a324.html", "date": "2026-03-28", "summary": "Vanguard Group has filed an amended Schedule 13G/A for QuidelOrtho (QDEL), reporting zero beneficial ownership of common stock. This change is due to an internal realignment where certain subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. Previously, these holdings were aggregated under The Vanguard Group, which now disclaims beneficial ownership of shares held by these subsidiaries.", "sentiment_score": 0.043754, "sentiment_label": "Neutral", "relevance_score": 0.33912, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Precision Trading with Quidelortho Corp Com (QDEL) Risk Zones", "url": "https://news.stocktradersdaily.com/news_release/151/Precision_Trading_with_Quidelortho_Corp_Com_QDEL_Risk_Zones_032726103202_1774665122.html", "date": "2026-03-27", "summary": "This article analyzes Quidelortho Corp Com (QDEL) with a short bias due to weak sentiment across all horizons, indicating a breakdown is underway. It provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, showing weak signals across near-term, mid-term, and long-term horizons, and highlights elevated downside risk.", "sentiment_score": -0.642831, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Recommendation of \"Reduce\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/quidelortho-corporation-nasdaqqdel-given-average-recommendation-of-reduce-by-brokerages-2026-03-26/", "date": "2026-03-26", "summary": "QuidelOrtho Corporation (NASDAQ:QDEL) has received an average \"Reduce\" rating from six brokerages, with a 12-month average price target of $31.50. Despite this, recent insider activity shows the CEO and CFO purchasing shares. The company reported better-than-expected Q4 earnings with revenue up 2.2% year-over-year, but still faces a negative net margin and PE ratio.", "sentiment_score": -0.28588, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer", "url": "https://www.barchart.com/story/news/914893/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer", "date": "2026-03-26", "summary": "QuidelOrtho Corporation has appointed Nathaniel \"Nate\" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky brings over 25 years of legal and governance experience from the life sciences and technology sectors and previously served as Chief Legal Officer at STAAR Surgical Company. He succeeds Michelle Hodges, who is retiring and will serve in an advisory role for a smooth transition.", "sentiment_score": 0.402114, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Medtech business QuidelOrtho hires STAAR Surgical legal head as CLO", "url": "https://www.globallegalpost.com/news/medtech-business-quidelortho-hires-staar-surgical-legal-head-as-clo-312927133", "date": "2026-03-25", "summary": "QuidelOrtho, a US medtech company, has appointed Nathaniel Sisitsky as its new Chief Legal Officer, succeeding the retiring Michelle Hodges. Sisitsky brings over 25 years of legal experience in life sciences and technology, joining from STAAR Surgical where he also served as CLO. He will be responsible for leading QuidelOrtho's global legal, compliance, and corporate governance functions.", "sentiment_score": 0.308825, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "QuidelOrtho names Nathaniel Sisitsky as chief legal officer By Investing.com", "url": "https://au.investing.com/news/company-news/quidelortho-names-nathaniel-sisitsky-as-chief-legal-officer-93CH-4327018", "date": "2026-03-25", "summary": "QuidelOrtho Corporation (NASDAQ:QDEL) has appointed Nathaniel Sisitsky as Chief Legal Officer, effective Monday, replacing Michelle Hodges, who is retiring. Sisitsky brings over 25 years of legal and governance experience in life sciences and technology sectors. The appointment comes as QuidelOrtho faces financial challenges, with its shares significantly down and the company carrying substantial debt, though analysts predict a return to profitability this year.", "sentiment_score": 0.417848, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (QDEL) Welcomes New Chief Legal Officer", "url": "https://www.gurufocus.com/news/8737950/quidelortho-qdel-welcomes-new-chief-legal-officer", "date": "2026-03-25", "summary": "QuidelOrtho (QDEL) has appointed Nathaniel \"Nate\" Sisitsky as its new Chief Legal Officer, effective March 23, to lead the company's global legal, compliance, and corporate governance activities. Sisitsky brings over 25 years of experience in life sciences and technology sectors. Despite this leadership enhancement, the company faces significant financial challenges, including declining revenue, negative profitability margins, high leverage, and a distress-level Altman Z-Score, suggesting potent", "sentiment_score": -0.261127, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "In Vitro Diagnostics Firm QuidelOrtho Picks New Legal Chief", "url": "https://news.bloomberglaw.com/business-and-practice/in-vitro-diagnostics-firm-quidelortho-picks-new-legal-chief", "date": "2026-03-24", "summary": "QuidelOrtho Corp., a leader in in vitro diagnostics, has appointed Nathaniel \"Nate\" Sisitsky as its new chief legal officer, effective March 24, 2026. Sisitsky brings over 25 years of legal and governance experience from the life sciences and technology sectors, having previously served as chief legal officer at STAAR Surgical Co. He succeeds Michelle Hodges, who is retiring.", "sentiment_score": 0.287762, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "In Vitro Diagnostics Firm QuidelOrtho Picks New Legal Chief", "url": "https://news.bloomberglaw.com/in-house-counsel/in-vitro-diagnostics-firm-quidelortho-picks-new-legal-chief", "date": "2026-03-24", "summary": "QuidelOrtho Corp., a global leader in in vitro diagnostics, has appointed Nathaniel \"Nate\" Sisitsky as its new chief legal officer, effective Monday. Sisitsky brings over 25 years of legal and governance experience, particularly within the life sciences and technology sectors, having most recently served as CLO at STAAR Surgical Co. He succeeds Michelle Hodges, who is retiring.", "sentiment_score": 0.132186, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Announces Chief Legal Officer Leadership Transition", "url": "https://www.tipranks.com/news/company-announcements/quidelortho-announces-chief-legal-officer-leadership-transition", "date": "2026-03-24", "summary": "QuidelOrtho (QDEL) has announced a leadership transition for its Chief Legal Officer role. Michelle A. Hodges will retire effective March 23, 2026, and transition into an advisory role for up to 24 months to ensure continuity. Nathaniel “Nate” Sisitsky, a seasoned legal executive with over 25 years of experience in life sciences and medtech, has been appointed as the new Chief Legal Officer and Corporate Secretary.", "sentiment_score": 0.013716, "sentiment_label": "Neutral", "relevance_score": 0.335101, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "QuidelOrtho names Nathaniel Sisitsky as chief legal officer", "url": "https://www.investing.com/news/company-news/quidelortho-names-nathaniel-sisitsky-as-chief-legal-officer-93CH-4577178", "date": "2026-03-24", "summary": "QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective Monday. Sisitsky, bringing over 25 years of legal and governance experience from the life sciences and technology sectors, will be responsible for the company's global legal, compliance, and corporate governance functions. This leadership change comes as QuidelOrtho faces financial challenges, including a 54% drop in share price over the past year and significant debt, although analysts predict a r", "sentiment_score": 0.043821, "sentiment_label": "Neutral", "relevance_score": 0.30299, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "QuidelOrtho hires ex-STAAR legal chief as Michelle Hodges retires", "url": "https://www.stocktitan.net/news/QDEL/nathaniel-sisitsky-joins-quidel-ortho-as-chief-legal-yrr4j4bgyqpd.html", "date": "2026-03-24", "summary": "QuidelOrtho (Nasdaq: QDEL) has appointed Nathaniel \"Nate\" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky brings over 25 years of legal experience in life sciences and technology, previously serving as Chief Legal Officer at STAAR Surgical. He succeeds Michelle Hodges, who is retiring but will remain in an advisory role during the transition.", "sentiment_score": 0.154528, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.994957, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer", "url": "https://www.prnewswire.com/news-releases/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer-302722706.html", "date": "2026-03-24", "summary": "QuidelOrtho Corporation has appointed Nathaniel \"Nate\" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky brings over 25 years of legal and governance experience in life sciences and technology, previously serving as Chief Legal Officer at STAAR Surgical Company. He will lead QuidelOrtho's global legal, compliance, and corporate governance functions, succeeding Michelle Hodges, who is retiring.", "sentiment_score": 0.405898, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (QDEL) Baird 2024 Global Healthcare Conference Summary", "url": "https://quartr.com/events/quidelortho-corporation-qdel-baird-2024-global-healthcare-conference_3spnj8P7", "date": "2026-03-24", "summary": "This article summarizes QuidelOrtho's presentation at the Baird 2024 Global Healthcare Conference, highlighting the stability and growth of its Labs segment, CEO transition, and strategic shift towards integrated instruments. The company focuses on cost realignment, continuous improvement, and capitalizing on geographic opportunities like China. It also provides a brief overview of recent financial events and guidance for QuidelOrtho.", "sentiment_score": 0.336124, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (QDEL) Morgan Stanley’s 22nd Annual Global Healthcare Conference summary", "url": "https://quartr.com/events/quidelortho-corporation-qdel-morgan-stanley-s-22nd-annual-global-healthcare-conference_3spnjcvA", "date": "2026-03-23", "summary": "QuidelOrtho's summary from Morgan Stanley's 22nd Annual Global Healthcare Conference highlights strategic shifts towards cost optimization, margin improvement, and renewed focus on customer satisfaction. Key drivers for future growth include stable Labs business with expected mid-single-digit growth in H2 2024, continued expansion in immunoassay share, and development in STI testing and menu expansion for the Savanna platform. The company also noted sustained high single-digit growth in its Chin", "sentiment_score": 0.440348, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (QDEL) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary", "url": "https://quartr.com/events/quidelortho-corporation-qdel-43rd-annual-j-p-morgan-healthcare-conference-2025_3spnfs9e", "date": "2026-03-23", "summary": "QuidelOrtho (QDEL) presented a summary of its operations and growth strategies at the 43rd Annual J.P. Morgan Healthcare Conference in 2025. The company detailed its market positioning across various diagnostic sectors, global reach, and leadership changes aimed at efficiency and innovation. Key growth drivers include its Labs business, Molecular Diagnostics with the Savanna platform, and a comprehensive product portfolio serving multiple care settings.", "sentiment_score": 0.420509, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QDEL SEC Filings - Quidel 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/QDEL/page-2.html", "date": "2026-03-22", "summary": "This page provides access to QuidelOrtho Corporation's SEC filings, including 10-K, 10-Q, and 8-K forms, offering comprehensive regulatory documents for investors. It highlights recent insider transactions, such as CFO Joseph Busky's RSU vesting and executive equity awards, and details major ownership changes like FMR LLC's 8% stake. The platform also notes board changes and provides AI-powered summaries for quick understanding of these complex financial disclosures.", "sentiment_score": 0.008107, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QDEL SEC Filings - Quidel 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/QDEL/page-5.html", "date": "2026-03-21", "summary": "This article provides a comprehensive overview of QuidelOrtho Corporation's (QDEL) SEC filings, including 10-K, 10-Q, and 8-K forms, accessible through the Stock Titan platform. It highlights how these filings inform investors about the company's financial condition, strategic decisions, and material events in the in vitro diagnostics and medical device manufacturing sector. The platform also offers AI-powered summaries to simplify complex regulatory documents for easier understanding.", "sentiment_score": 0.120928, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp stock hits new 52-week low amid persistent financial struggles and biotech sector headwinds", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/quidelortho-corp-stock-hits-new-52-week-low-amid-persistent-financial/68947768", "date": "2026-03-21", "summary": "QuidelOrtho Corp's stock has plummeted to a new 52-week low of $16.16 USD, reflecting 12 consecutive quarters of losses and high debt levels. The company, specializing in in-vitro diagnostics, faces significant financial strain as post-pandemic demand for COVID-19 tests wanes and integration costs from its merger with Ortho Clinical Diagnostics weigh heavily. Despite a low price-to-book ratio suggesting potential value, persistent losses and high short interest signal investor skepticism, necess", "sentiment_score": -0.405943, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.557, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp. Hits Day Low of $16.16 Amid Price Pressure", "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-hits-day-low-of-1616-amid-price-pressure-3903714", "date": "2026-03-20", "summary": "QuidelOrtho Corp., a Pharmaceuticals & Biotechnology sector company, experienced significant stock volatility, hitting an intraday low of $16.16, with a year-to-date decline of nearly 42%. The company's financial performance is concerning, marked by a high debt-equity ratio and negative return on equity. These figures highlight the ongoing challenges QuidelOrtho faces in the market.", "sentiment_score": -0.826978, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp. Stock Plummets to New 52-Week Low at $17.03", "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-stock-plummets-to-new-52-week-low-at-1703-3900959", "date": "2026-03-19", "summary": "QuidelOrtho Corp. reached a new 52-week low of $17.03 on March 18, 2026, marking a significant decline of 58.58% over the past year. The company, with a market capitalization of USD 1,202 million, has reported negative results for 12 consecutive quarters and has a high debt-equity ratio of 1.31. Its performance considerably lags the S&P 500's gain of 17.99% over the same period, indicating ongoing financial challenges.", "sentiment_score": -0.735464, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating", "url": "https://www.msn.com/en-us/money/topstocks/rbc-capital-raises-pt-on-quidelortho-corporation-from-60-to-62-keeps-buy-rating/ar-AA1MeGFo?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1", "date": "2026-03-18", "summary": "RBC Capital has increased its price target for QuidelOrtho Corporation (QDEL) from $60 to $62, while maintaining a Buy rating on the stock. This adjustment reflects continued confidence in the company's performance and future outlook from the analyst firm.", "sentiment_score": 0.496766, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating", "url": "http://www.msn.com/en-us/money/topstocks/rbc-capital-raises-pt-on-quidelortho-corporation-from-60-to-62-keeps-buy-rating/ar-AA1MeGFo?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1", "date": "2026-03-18", "summary": "RBC Capital has increased its price target for QuidelOrtho Corporation (QDEL) from $60 to $62, while maintaining a Buy rating on the stock. This adjustment reflects continued confidence in the company's financial outlook and market position. The decision by RBC Capital suggests a positive long-term view for QuidelOrtho.", "sentiment_score": 0.443101, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho (NASDAQ:QDEL) Trading Down 8.3% - Should You Sell?", "url": "https://www.marketbeat.com/instant-alerts/quidelortho-nasdaqqdel-trading-down-83-should-you-sell-2026-03-18/", "date": "2026-03-18", "summary": "QuidelOrtho (NASDAQ:QDEL) shares dropped 8.3% to $17.54 on Wednesday, trading significantly below average volume. Analyst sentiment is generally bearish, with a consensus \"Reduce\" rating and an average price target of $31.50, despite the company slightly beating EPS and revenue estimates but reporting a large negative net margin. Insiders, including the CEO and CFO, have recently purchased shares, indicating some internal confidence.", "sentiment_score": -0.342718, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp. Hits Day High with Strong 8.33% Intraday Surge", "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-hits-day-high-with-strong-833-intraday-surge-3899204", "date": "2026-03-18", "summary": "QuidelOrtho Corp., a small-cap pharmaceutical company, saw its stock surge by 8.33% to an intraday high of USD 19.72, despite a year of significant decline (47.18%) and poor financial metrics. The company has a high debt-equity ratio, low interest coverage, and negative return on equity, indicating ongoing challenges. Today's rise offers a brief positive interlude amidst continuous underperformance compared to the S&P 500.", "sentiment_score": -0.241328, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp Stock (ISIN: US7476011036) Faces Institutional Shifts Amid Diagnostics Recovery Signals", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/quidelortho-corp-stock-isin-us7476011036-faces-institutional-shifts/68688182", "date": "2026-03-15", "summary": "QuidelOrtho Corp (ISIN: US7476011036) stock is trading at $17.10, showing mixed institutional activity with some firms acquiring shares and others selling, amid a backdrop of post-pandemic challenges in diagnostics. UBS maintains a $30 price target, signaling over 75% upside potential despite the company's ongoing losses. European investors are viewing QuidelOrtho as a value play with long-term recovery potential driven by its diagnostics installed base and consumables business model.", "sentiment_score": 0.023646, "sentiment_label": "Neutral", "relevance_score": 0.337882, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corporation $QDEL Shares Acquired by Aristotle Capital Boston LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-quidelortho-corporation-qdel-shares-acquired-by-aristotle-capital-boston-llc-2026-03-15/", "date": "2026-03-15", "summary": "Aristotle Capital Boston LLC significantly increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 62.4% in the third quarter, acquiring an additional 146,956 shares. This investment signals institutional confidence, further reinforced by recent insider purchases from the CEO and CFO. Despite this, analyst sentiment remains mixed, with a consensus \"Reduce\" rating and a target price of $31.50 for the diagnostic solutions company.", "sentiment_score": 0.001138, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "ArrowMark Colorado Holdings LLC Sells 181,325 Shares of QuidelOrtho Corporation $QDEL", "url": "https://www.marketbeat.com/instant-alerts/filing-arrowmark-colorado-holdings-llc-sells-181325-shares-of-quidelortho-corporation-qdel-2026-03-15/", "date": "2026-03-15", "summary": "ArrowMark Colorado Holdings LLC reduced its stake in QuidelOrtho Corporation by 18.8% in the third quarter, selling 181,325 shares and now owning 782,954 shares valued at $23.06 million. Despite this, company insiders, including CFO Joseph M. Busky and Director Matthew Strobeck, increased their holdings. QuidelOrtho exceeded revenue and EPS estimates but reported a negative net margin, with Wall Street maintaining a \"Reduce\" rating and a $31.50 price target.", "sentiment_score": -0.238817, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.972914, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "QuidelOrtho Corp. Experiences Revision in Stock Evaluation Amid Market Challenges", "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corps-technical-trend-changes-from-mildly-bearish-to-bearish-amid-stock-decline-3889190", "date": "2026-03-13", "summary": "QuidelOrtho Corp. has undergone a stock evaluation revision due to challenging market conditions, with its price at $17.92, reflecting a 51.40% decline over the past year against the S&P 500's rise. Technical indicators are predominantly bearish, and the stock has dropped 86.84% over five years, highlighting significant struggles in the pharmaceuticals and biotechnology sector.", "sentiment_score": -0.625884, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41910522", "title": "Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction: From Institutional Recognition to Clinical Integration.", "authors": "Packer M et al.", "journal": "JACC. Heart failure", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41910522/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41903165", "title": "EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF.", "authors": "Chimura M et al.", "journal": "JAMA cardiology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903165/", "sentiment": { "label": "negative", "score": -0.473, "confidence": 0.47 } }, { "source": "pubmed", "pmid": "41879583", "title": "High-Sensitivity Cardiac Troponin T-gen6 Assay in Suspected Myocardial Infarction: Diagnostic Accuracy, Cutoffs, and Clinical Implications.", "authors": "Koechlin L et al.", "journal": "Journal of the American College of Cardiology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41879583/", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41740461", "title": "The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.", "authors": "Whitaker JA et al.", "journal": "Vaccine", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41740461/", "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "pubmed", "pmid": "41670567", "title": "Heart Failure With Preserved Ejection Fraction: Clinical Judgment Beyond Diastolic Algorithms.", "authors": "Cannata A et al.", "journal": "Journal of the American College of Cardiology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41670567/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41627802", "title": "Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.", "authors": "Pop-Busui R et al.", "journal": "JAMA internal medicine", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41627802/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } } ] } }